STOCKHOLM, Sweden, Sept. 15, 2009 (GLOBE NEWSWIRE) -- The Diamyd Medical Board of Directors has, subject to approval at the shareholder's meeting, decided to implement a preferential rights issue of 220 MSEK. The new share issue strengthens Diamyd's negotiation position in the ongoing process to find an industrial partner as well as secures financing of the Phase III studies. The rights issue is 100% underwritten through undertakings by existing shareholders and underwriters.
